Search

Displaying results 2501 - 2510 of 5506 in total
  1. Drug

    ETC-1001

    go.drugbank.com/drugs/DB05866
    Experimental

    ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.

  2. Drug

    CZEN 002

    go.drugbank.com/drugs/DB05479
    Experimental

    It appears that CZEN-002 works on a receptor in yeast that has yet to be identified. … The antimicrobial activity of CZEN-002 is unique in that it does not depend on direct damage to the microbial membrane.

  3. Drug

    Urea C-14

    go.drugbank.com/drugs/DB09513
    ApprovedInvestigational

    It is currently used for the Urea Breath Test (UBT) and is available as a rapid diagnostic test (marketed as PyTest) for the detection of Helicobacter pylori infections. … Both forms can be used within the Urea Breath Test, however some may prefer 13C as it is non-radioactive compared to 14C, which may be preferable in pregnant women and children.

  4. Drug

    Vanoxerine

    go.drugbank.com/drugs/DB03701
    Investigational

    It was synthesized in the late 1970s and developed as a potential treatment for depression. … [A37914] Although several studies have suggested that the profile of vanoxerine is safer than that of cocaine,[A19824,A248550] other studies have found that vanoxerine has at least moderate potential to

  5. Drug

    Sar9, Met (O2)11-Substance P

    go.drugbank.com/drugs/DB05875
    Investigational

    Sar9, Met (O2)11-Substance P is a neurokinin-1 receptor agonist. … It is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species.

    Synonyms: (Sar(9),met(O2)(11))SP, 9-Sar-11-met(O2)-substance P
  6. Drug

    Inavolisib

    go.drugbank.com/drugs/DB15275
    ApprovedInvestigational

    [L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605] … _PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation.

  7. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD

  8. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    [L13772] It is marketed under the brand name Ongentys as once-daily oral capsules. … [A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management

  9. Drug

    Cysteine

    go.drugbank.com/drugs/DB00151
    ApprovedInvestigationalNutraceutical

    A thiol-containing non-essential amino acid that is oxidized to form cystine.

    Mixtures: Numeta G 13 % E Emulsion zur Infusion, Numeta G 16 % E Emulsion zur InfusionProducts: L Cysteine HCl Inj 50mg/ml
  10. Drug

    Bremelanotide

    go.drugbank.com/drugs/DB11653
    Approved

    [L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141. … [A179683] Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women.